



**Final Appraisal Recommendation**

Advice No: 0219 – February 2019

**Ciclosporin (Verkazia®) 1 mg/ml eye drops, emulsion**

**Submission by Santen UK Limited**

**Recommendation of AWMSG**

**Ciclosporin (Verkazia®) is recommended as an option for use within NHS Wales for the treatment of severe vernal keratoconjunctivitis in children from 4 years of age and adolescents (until the age of 18).**

**Additional note(s):**

- AWMSG considered that ciclosporin (Verkazia®) satisfied the AWMSG criteria for orphan status.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2908), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0219:  
Ciclosporin (Verkazia®) 1mg/ml eye drops, emulsion February 2019